Dr Colombel discusses his presentation at DDW 2026 on a post-doc analysis of the long-term outcomes of the LUCENT trial of mirikizumab, which showed that the IL-23p19 inhibitor achieved and maintained disease clearance for up to 4 years among...
Dr Colombel discusses his presentation at DDW 2026 on a post-doc analysis of the long-term outcomes of the LUCENT trial of mirikizumab, which showed that the IL-23p19 inhibitor achieved and maintained disease clearance for up to 4 years among...
Dr Colombel discusses his...